BOLD BOUNDLESS BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, BOUNDLESS BIO INC reported revenue of n/a, net income of −$23.7M and diluted EPS of −$1.06; for the fiscal year ended December 2025 revenue was n/a.
BOLD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$63.6M, net income −$58.2M (margin n/a), EPS −$2.60
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$73.3M, net income −$65.4M (margin n/a), EPS −$3.85
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$54.8M, net income −$49.4M (margin n/a), EPS −$40.65
BOLD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$23.7M, EPS −$1.06
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.6M, EPS −$0.60
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$12.9M, EPS −$0.57
- Quarter ended Sep 30, 2025: revenue n/a, net income −$13.9M, EPS −$0.62
- Quarter ended Jun 30, 2025: revenue n/a, net income −$15.7M, EPS −$0.70
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.8M, EPS −$0.71
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$16.4M, EPS $9.93
- Quarter ended Sep 30, 2024: revenue n/a, net income −$16.5M, EPS −$0.74
- Quarter ended Jun 30, 2024: revenue n/a, net income −$17.0M, EPS −$0.77
- Quarter ended Mar 31, 2024: revenue n/a, net income −$15.4M, EPS −$12.27
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$12.1M, EPS −$9.75
- Quarter ended Sep 30, 2023: revenue n/a, net income −$13.2M, EPS −$10.71
- Quarter ended Jun 30, 2023: revenue n/a, net income −$12.4M, EPS −$10.28
- Quarter ended Mar 31, 2023: revenue n/a, net income −$11.7M, EPS −$9.91
BOLD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$46.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$60.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$46.9M, share buybacks n/a
BOLD balance sheet
- Jun 30, 2026: cash $20.2M, total assets $73.7M, total liabilities $7.77M, shareholders' equity $66.0M
- Mar 31, 2026: cash $17.5M, total assets $141M, total liabilities $54.6M, shareholders' equity $86.4M
- Dec 31, 2025: cash $17.9M, total assets $157M, total liabilities $58.4M, shareholders' equity $98.7M
- Sep 30, 2025: cash $15.0M, total assets $169M, total liabilities $58.6M, shareholders' equity $110M
- Jun 30, 2025: cash $14.7M, total assets $179M, total liabilities $56.8M, shareholders' equity $123M
- Mar 31, 2025: cash $15.1M, total assets $191M, total liabilities $54.7M, shareholders' equity $137M
- Dec 31, 2024: cash $26.6M, total assets $206M, total liabilities $55.8M, shareholders' equity $151M
- Sep 30, 2024: cash $40.2M, total assets $175M, total liabilities n/a, shareholders' equity $165M
Is BOLD profitable?
No. BOUNDLESS BIO INC lost $64.0M over the last four quarters.
What is BOLD's EPS?
Diluted earnings per share over the last four quarters were −$2.85; −$1.06 in the latest quarter.